| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 131, 2733-2741, Copyright © 1992 by Endocrine Society
ARTICLES |
EP Smith, PT Cheung, A Ferguson and SD Chernausek
Division of Endocrinology, Children's Hospital Medical Center, Cincinnati, Ohio 45229.
FSH, which stimulates cAMP in the Sertoli cell, markedly lowers the concentration of insulin-like growth factor-binding protein-3 (IGFBP-3) in Sertoli cell-conditioned medium; in contrast, insulin-like growth factor-I (IGF-I) increases BP-3 expression. In this study, the mechanisms controlling the contrasting effects of cAMP and IGF-I were investigated. The abundance of BP-3 mRNA was dramatically lowered by (Bu)2cAMP, but was unaffected by IGF-I. Analyzed by ligand blot of conditioned medium, coincubation of (Bu)2cAMP and IGF-I largely eliminated the increase observed with IGF-I alone. Based on the following evidence, the effect of IGF-I appeared to be solely related to the capacity of IGF-I to interact directly with BP-3. 1) Insulin at micromolar concentrations failed to increase BP-3 abundance despite documentation by affinity cross-linking that insulin displaced [125I]IGF-I from the IGF-I receptor. 2) A synthetic IGF-I analog, [Leu24,1-62]IGF-I, which has reduced binding affinity for rat IGF-I receptor but displays high affinity for rat Sertoli cell-conditioned medium BPs, increased BP-3 abundance. 3) A synthetic IGF-I analog, B- chain mutant, which has reduced affinity for rat Sertoli cell BPs but displays normal affinity for the rat IGF-I receptor, failed to increase BP-3 abundance. 4) Human recombinant glycosylated [125I]BP-3 when added to cultured Sertoli cells was preserved in the medium when IGF-I or analogs with BP-3 affinity were present. 5) IGF-I, in dose-responsive manner, both retarded the disappearance from the medium of exogenously added human recombinant nonglycosylated BP-3 and decreased the amount of membrane-associated BP-3. These results indicate that whereas cAMP lowers BP-3 abundance in medium, most likely by markedly decreasing synthesis, IGF-I increases BP-3 accumulation by retarding its clearance by the Sertoli cell.
This article has been cited by other articles:
![]() |
N. Bhattacharyya, K. Pechhold, H. Shahjee, G. Zappala, C. Elbi, B. Raaka, M. Wiench, J. Hong, and M. M. Rechler Nonsecreted Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Can Induce Apoptosis in Human Prostate Cancer Cells by IGF-independent Mechanisms without Being Concentrated in the Nucleus J. Biol. Chem., August 25, 2006; 281(34): 24588 - 24601. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. I. Sadate-Ngatchou, D. J. Pouchnik, and M. D. Griswold Follicle-Stimulating Hormone Induced Changes in Gene Expression of Murine Testis Mol. Endocrinol., November 1, 2004; 18(11): 2805 - 2816. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Khan, L. Ndjountche, L. Pratchard, L. J. Spicer, and J. S. Davis Follicle-Stimulating Hormone Amplifies Insulin-Like Growth Factor I-Mediated Activation of AKT/Protein Kinase B Signaling in Immature Rat Sertoli Cells Endocrinology, June 1, 2002; 143(6): 2259 - 2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, X. Ma, L.-C. C. Yeh, and M. L. Adamo Differential Regulation of IGF-Binding Protein Gene Expression by cAMP in Rat C6 Glioma Cells Endocrinology, September 1, 2001; 142(9): 3917 - 3925. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |